Literature DB >> 20574815

A controlled study of risk factors for disease and current problems in long-term testicular cancer survivors.

Christian Falk Dahl1, Hege Sagstuen Haugnes, Roy Bremnes, Olav Dahl, Sophie D Fosså, Olbjørn Klepp, Erik Wist, Alv A Dahl.   

Abstract

INTRODUCTION: To compare risk factors for disease and current problems in long-term testicular cancer survivors (TCSs) and age-matched population-based controls (NORMs).
METHODS: The study was cross-sectional and concerned 1,291 Norwegian TCSs followed up after a mean of 11 years, and 6,455 NORMs. Both TCSs and NORMs completed questionnaires and had a clinical examination. Indices for risk factors and current problems were calculated. Outcome measures were: visits to general practitioners last year, poor self-rated health, and poor quality of life (QoL).
RESULTS: The mean risk score was significantly lower and the mean current problem score significantly higher in TCSs compared to NORMs without reaching clinical significance. The risk for future fatal cardiac events did not differ between the groups. TCSs had a higher risk for visiting a general practitioner than NORMs (OR 3.58, 95% CI 3.09-4.15), while no significant difference was observed for self-rated health. Poor QoL in TCSs was significantly associated with more current problems than risk factors. Previous treatment for mental problems, presence of severe somatic disease and musculo-skeletal problems were significantly associated with all three outcome measures. Musculo-skeletal problems were most strongly associated with visits to general practitioners among TCSs.
CONCLUSIONS: Several risk factors for preventive clinical interventions and current problems that eventually should be treated were identified in TCSs. IMPLICATIONS FOR CANCER SURVIVORS: TCSs show several risk factors and current problems that are relevant for visits to general practitioners, poorer self-rated health, and poorer QoL. These should get attention from health personnel caring for TCSs.

Entities:  

Mesh:

Year:  2010        PMID: 20574815     DOI: 10.1007/s11764-010-0133-y

Source DB:  PubMed          Journal:  J Cancer Surviv        ISSN: 1932-2259            Impact factor:   4.442


  25 in total

Review 1.  Effect size, confidence interval and statistical significance: a practical guide for biologists.

Authors:  Shinichi Nakagawa; Innes C Cuthill
Journal:  Biol Rev Camb Philos Soc       Date:  2007-11

Review 2.  Exercise for the management of cancer-related fatigue in adults.

Authors:  F Cramp; J Daniel
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

3.  Components of the metabolic syndrome in long-term survivors of testicular cancer.

Authors:  H S Haugnes; N Aass; S D Fosså; O Dahl; O Klepp; E A Wist; J Svartberg; T Wilsgaard; R M Bremnes
Journal:  Ann Oncol       Date:  2006-10-23       Impact factor: 32.976

4.  Pain as a reason to visit the doctor: a study in Finnish primary health care.

Authors:  P Mäntyselkä; E Kumpusalo; R Ahonen; A Kumpusalo; J Kauhanen; H Viinamäki; P Halonen; J Takala
Journal:  Pain       Date:  2001-01       Impact factor: 6.961

5.  Study of anxiety disorder and depression in long-term survivors of testicular cancer.

Authors:  Alv A Dahl; Carl Fredrik Haaland; Arnstein Mykletun; Roy Bremnes; Olav Dahl; Olbjørn Klepp; Erik Wist; Sophie D Fosså
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

6.  Is the sexual function compromised in long-term testicular cancer survivors?

Authors:  Alv A Dahl; Roy Bremnes; Olav Dahl; Olbjørn Klepp; Erik Wist; Sophie D Fosså
Journal:  Eur Urol       Date:  2007-03-01       Impact factor: 20.096

7.  The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample.

Authors:  Lene Thorsen; Wenche Nystad; Hein Stigum; Olav Dahl; Olbjørn Klepp; Roy M Bremnes; Erik Wist; Sophie D Fosså
Journal:  Support Care Cancer       Date:  2005-03-09       Impact factor: 3.603

8.  Fear of recurrence in long-term testicular cancer survivors.

Authors:  Tone Skaali; Sophie D Fosså; Roy Bremnes; Olav Dahl; Carl Fredrik Haaland; Erik Rønneberg Hauge; Olbjørn Klepp; Jan Oldenburg; Erik Wist; Alv A Dahl
Journal:  Psychooncology       Date:  2009-06       Impact factor: 3.894

9.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.

Authors:  R M Conroy; K Pyörälä; A P Fitzgerald; S Sans; A Menotti; G De Backer; D De Bacquer; P Ducimetière; P Jousilahti; U Keil; I Njølstad; R G Oganov; T Thomsen; H Tunstall-Pedoe; A Tverdal; H Wedel; P Whincup; L Wilhelmsen; I M Graham
Journal:  Eur Heart J       Date:  2003-06       Impact factor: 29.983

10.  The value of the CAGE in screening for alcohol abuse and alcohol dependence in general clinical populations: a diagnostic meta-analysis.

Authors:  B Aertgeerts; F Buntinx; A Kester
Journal:  J Clin Epidemiol       Date:  2004-01       Impact factor: 6.437

View more
  2 in total

1.  Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.

Authors:  Chunkit Fung; Howard D Sesso; Annalynn M Williams; Sarah L Kerns; Patrick Monahan; Mohammad Abu Zaid; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Christian K Kollmannsberger; Ryan Cook; Sandra Althouse; Shirin Ardeshir-Rouhani-Fard; Steve E Lipshultz; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis
Journal:  J Clin Oncol       Date:  2017-02-27       Impact factor: 44.544

2.  Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

Authors:  Sarah L Kerns; Chunkit Fung; Patrick O Monahan; Shirin Ardeshir-Rouhani-Fard; Mohammad I Abu Zaid; AnnaLynn M Williams; Timothy E Stump; Howard D Sesso; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair Beard; Robert A Huddart; Jeri Kim; Christian Kollmannsberger; Deepak M Sahasrabudhe; Ryan Cook; Sophie D Fossa; Lawrence H Einhorn; Lois B Travis
Journal:  J Clin Oncol       Date:  2018-04-04       Impact factor: 44.544

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.